Scarica l'app Stockscreener
273.45
0.03%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$273.37
Aprire:
$273.37
Volume 24 ore:
594.21K
Relative Volume:
0.67
Capitalizzazione di mercato:
$40.08B
Reddito:
$5.02B
Utile/perdita netta:
$1.31B
Rapporto P/E:
30.69
EPS:
8.91
Flusso di cassa netto:
$1.56B
1 W Prestazione:
+6.65%
1M Prestazione:
+6.86%
6M Prestazione:
+9.16%
1 anno Prestazione:
+32.62%
Intervallo 1D:
$271.01
$274.00
Intervallo di 1 settimana:
$256.53
$274.00
Portata 52W:
$196.43
$274.00
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
273.35 | 39.21B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
488.64 | 183.15B | 9.15B | 2.61B | 1.75B | 7.17 |
|
BDX
Becton Dickinson Co
|
183.62 | 51.96B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
91.89 | 43.85B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
278.21 | 15.73B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
What analysts say about ResMed Inc. stockSuperior portfolio returns - jammulinksnews.com
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
If You Invested $1000 in ResMed a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Here's What To Expect From ResMed's Next Earnings Report - Barchart.com
MIN and Resmed CDI: 2 ASX shares to dig into - Rask Media
ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
What drives ResMed Inc. stock priceFree Investment Timing Strategies - jammulinksnews.com
ResMed Inc. Stock Analysis and ForecastFree Investment Portfolio Suggestions - Autocar Professional
Is ResMed Inc. a good long term investmentMarket-beating returns - jammulinksnews.com
ResMed stock hits 52-week high at 263.62 USD By Investing.com - Investing.com Nigeria
Sleep Apnea Devices Market is expected to generate a revenue of USD 14.59 Billion by 2031, Globally, at 10.42 % CAGR: Verified Market Research® - GlobeNewswire Inc.
Published on: 2025-07-19 18:08:41 - jammulinksnews.com
What makes ResMed Inc. stock attractive to long term investorsTrend Based Entry Alerts - beatles.ru
This ResMed Insider Reduced Their Stake By 72% - simplywall.st
This Pick Withstood the GLP-1 Challenge. Stick With the Stock. - Barron's
Analyst Expectations For ResMed's Future - Nasdaq
ResMed (RMD) Price Target Increased to $270 by Mizuho Analyst | - GuruFocus
Brokers Set Expectations for ResMed's Q1 Earnings (NYSE:RMD) - MarketBeat
RBC Upgrades ResMed to Outperform From Sector Perform, Adjusts Price Target to $294 From $255 - MarketScreener
ResMed's Trading Volume Surges 78.7% to 2.35 Billion, Stock Price Drops 0.11% Placing 406th in Market Rankings - AInvest
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - 富途牛牛
ResMed CEO Executes Stock Transactions Under Rule 10b5-1 Plan - TipRanks
Resmed CEO Farrell sells $2.06 million in stock By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $2,056,076, According to a Recent SEC Filing - MarketScreener
ResMed Inc. Officer Plans Sale of Common Stock Under Rule 144 - TipRanks
With 75% institutional ownership, ResMed Inc. (NYSE:RMD) is a favorite amongst the big guns - simplywall.st
ResMed CFO Reports Changes in Stock Ownership - TipRanks
ResMed to Release Q4 2025 Financial Results on July 31, 2025, via Webcast - AInvest
ResMed Executives Sell Shares Under Pre-arranged Trading Plans - TradingView
ResMed Director Announces Further Share Sale - TipRanks
ResMed Chief Legal Officer Sells Shares - MarketScreener
Resmed Inc Officer Files Notice for Stock Sale Under Rule 144 - TipRanks
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025 | RMD Stock News - GuruFocus
Resmed Announces Fourth Quarter Fiscal Year 2025 Financial Results Release and Webcast Details - Quiver Quantitative
ResMed (NYSE:RMD) Shows Growth in ROCE and Business Efficiency NYSE Composite - Kalkine Media
ResMed (NYSE:RMD) Could Become A Multi-Bagger - Yahoo Finance
Zacks.com featured highlights Sprouts Farmers Market, Adobe, GE Aerospace and ResMed - Yahoo Finance
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy - Nasdaq
Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com
ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN
ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews
ResMed Stock: Is RMD Outperforming The Healthcare Sector? - Barchart.com
Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa
ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.30%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):